Haemonetics Corporation (HAE) Financials
Key financial figures for Haemonetics Corporation (Q2 2027).
Haemonetics fiscal Q2 2027 revenue rose 9.3% to $357.8M with adjusted EPS of $1.35, and full-year reported revenue growth guidance was raised to 8-11% from 5-8%. Revenue was $357.8M, up 9.3% reported and 10.0% organic. Apheresis revenue was $204.8M (up 12.6%, Plasma $162.6M up 16.5%) and MedSurg was $153.0M (up 5.1%). GAAP diluted EPS was $1.00 against $0.81 a year earlier; adjusted diluted EPS was $1.35 against $1.27, up 6.3%. Gross margin was 61.7% against 59.5%, helped by tariffs refunded, a richer product mix and no inventory step-up amortization; operating income was $75.1M (21.0% margin) against $58.5M (17.9%). On the outlook: Fiscal 2027 guidance updated: reported revenue growth 8-11% (previously 5-8%), including a roughly 2% drag from the 53rd week, about 1% from strategic exits and 0-1% currency; organic revenue growth 6-9% (previously 4-7%), with high-single-digit growth in Apheresis and mid-single-digit growth in MedSurg; adjusted operating margin expansion of 0-50 basis points year over year (previously 50-100); adjusted EPS growth comparable to reported revenue growth (unchanged); free cash flow conversion above 80% (previously about 80%). Figures are for Q2 FY2027, as Haemonetics reported them.
- Revenue
- $358M
- Net Income
- $46M
- EPS
- $1.02
- Total Assets
- $2.4B
- Operating Cash Flow
- $128M
Recent quarters
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| Q2 FY2027 | $358M | $46M | $1.00 | 21% | $119M |
| Q1 FY2027 | $339M | $33M | $0.72 | 16.93% | $44M |
| Q4 FY2026 | $346M | -$20M | -$0.44 | 14.85% | $53M |
| Q3 FY2026 | $339M | $45M | $0.95 | 20.52% | $87M |
| Q2 FY2026 | $327M | $39M | $0.81 | 20.55% | $106M |
Recent fiscal years
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| FY2026 | $1.3B | $97M | $2.05 | 11.75% | $260M |
| FY2025 | $1.4B | $168M | $3.31 | 16.3% | $142M |
| FY2024 | $1.3B | $118M | $2.29 | 12.6% | $144M |
Frequently asked questions
What was Haemonetics's revenue last quarter?
Haemonetics reported revenue of $357.8 million for Q2 FY2027, up 9.3% from the same period a year earlier.
Is Haemonetics profitable?
Yes. Haemonetics reported net income of $46.3 million for Q2 FY2027, a net margin of 12.94% on revenue.
How has Haemonetics's margin trended?
Operating margin was 21% in Q2 FY2027, compared with 20.55% in the same period a year earlier. The quarter by quarter series is on the SentiSense financials page.
How much free cash flow did Haemonetics generate?
Haemonetics generated free cash flow of $118.9 million in Q2 FY2027, after capital expenditure.
Full income statement, balance sheet and cash flow for Haemonetics Corporation on SentiSense, with up to forty quarters and twenty fiscal years of history.